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Pulmonary Haemosiderosis Secondary to Hereditary Haemochromatosis; a 
Case Report
Abstract
Introduction: Hereditary haemochromatosis (HH) is an autosomal recessive 
disease of increased intestinal absorption of iron, leading to accumulation 
in tissues which may progress to organ damage, most commonly in the 
liver. Iron deposition in the liver can lead to cirrhosis and hepatocellular 
carcinoma. Other common manifestations of haemochromatosis include 
diabetes, bronzing of the skin, arthropathy and cardiomyopathy. Here, 
we describe a case of pulmonary haemosiderosis secondary to HH. 
Case Description: A 49-year-old male with no medical history or family 
history of iron overload presented with fatigue, shortness of breath and 
chest pain after a recent finding of elevated ferritin. The patient was found 
to have biallelic C282Y mutations of the human homeostatic iron regulator 
protein (HFE) protein and after further workup with laboratory tests and 
imaging was diagnosed with HH with secondary pulmonary haemosiderosis. 
The patient is receiving twice weekly phlebotomies and has had an overall 
improvement in his symptoms. Practical Implications: The presentation 
of haemochromatosis can vary widely depending on the severity of iron 
overload and the presence of conditions that predispose organ dysfunction. 
Pulmonary haemosiderosis is a very rare manifestation of HH. This report 
illustrates the various manifestations of this disease and provides insight 
into this rare presentation to improve the diagnosis of this disease.
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Introduction
Hereditary haemochromatosis (HH) is an autosomal 
recessive condition of dysregulated iron absorption 
that may lead to an overload of total body iron with 
associated secondary tissue damage. The genetic 
prevalence of this disorder is 0.4% in Northern 
Europeans; however, it has a much lower clinical 
prevalence.[1] Individuals with a homozygous 
substitution of tyrosine for cysteine at position 282 
(C282Y) in the HFE protein account for 82–90% 
of the clinical diagnosis of HH among Northern 
Europeans descendants.[2] Elevated serum ferritin 
and transferrin saturation (TSAT) occur more 
frequently in males with C282Y homozygosity than 
females with the same amino acid substitution.[3-5] 
European Association for the Study of the Liver 
defines HH as C282Y homozygosity and increased 
body iron stores with or without clinical symptoms.[1]
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Iron accumulation associated with HH may present 
in a variety of ways. Elevated serum alanine 
aminotransferase levels indicating that hepatic 
dysfunction is an early manifestation of this disease 
and may progress to cirrhosis and hepatocellular 
carcinoma.[6,7] Iron may accumulate in the skin, 
leading to pigmentation as well as in endocrine 
organs resulting in hypothyroidism, diabetes mellitus 
and hypogonadism.[8,9] In a severely iron overloaded 
state, cardiomyopathy may occur resulting in 
arrhythmias and heart failure.[10] Here, we describe HH 
presenting with pulmonary haemosiderosis which is 
a rare presenting manifestation of this disease.
Case Report
A 49-year-old White male with no significant 
medical history or family history of iron overload 
was referred to haematology oncology for further 
evaluation of an elevated ferritin. The patient had 
not seen a medical provider for many years before 
a recent visit to an urgent care clinic for fatigue 
and left-sided face and left extremity paresthesia. 
On further workup including possible Vitamin 
B12 deficiency, he was found to have elevated 
haemoglobin of 17.6 g/dl, a ferritin level above 
1300  ng/mL with a normal Vitamin B12 level, 
white blood cell and platelet counts. A referral to 
haematology oncology department was placed.
Four weeks after the urgent care visit, the patient 
presented to the emergency room with episodes of 
shortness of breath and chest pain. His chest X-ray 
showed fine reticular nodular pattern throughout 
the entirety of both lungs concerning for pulmonary 
haemosiderosis [Figure  1]. His electrolytes and 
liver function test were within normal limits. His 
workup showed normal Vitamin B12 levels and an 
elevated ferritin level of 1913 ng/mL. He denied 
any major issues or problems. On further workup 
at the haematology clinic, he specifically denied 
any history of diabetes, chest tenderness, joint 
pain, shortness of breath, cough, haemoptysis, 
history of prior lung disease, frequent respiratory 
illnesses, fever, chills, night sweats and gastro-
oesophageal reflux disease. Before diagnosis, he 
was going to the gym regularly using the treadmill 
and light weights without limitation. He endorsed 
having fatigue and numbness and tingling in his 
hands and feet. He denied any other joint arthritis 
or darkening of the skin. He had no family history 
of iron overload and had no offspring. He was a 
former smoker and quit 1  week before the visit. 
He denied any alcohol consumption. His physical 
examination was completely benign.
The blood haemochromatosis human homeostatic 
iron regulator protein (HFE) gene analysis showed 
Figure  1: Chest X-ray showing fine reticular nodular 
pattern throughout the entirety of both lungs concerning 
for pulmonary haemosiderosis
Figure 2: Computed tomography chest showing diffuse 
reticular nodular opacities consistent with pulmonary 
haemosiderosis
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two copies of the C282Y mutation. This result can 
take place in patients with HH. However, it does 
not confirm a diagnosis or predisposition to the 
development of HH. Computed tomography 
(CT) chest showed diffuse reticular nodular 
opacities which are consistent with pulmonary 
haemosiderosis[11] [Figure 2]. Likewise, the patient 
underwent FerriScan (Resonance Health, Burswood, 
Western Australia, Australia) which showed no focal 
abnormality on non-contrast sequences and marked 
T2 hypointensity of the liver which is consistent with 
iron deposition. FerriScan transverse relaxation rate 
shows that TSAT was >45% and his liver iron content 
per dry liver weight was approximately 29 mg/g 
(normal is <1.8 mg/g) [Figure 3].
Diagnosis and Management
Differential included interstitial lung disease 
due to his smoking history as well as pulmonary 
haemosiderosis. Given the elevated ferritin, two 
copies of the C282Y mutation and the imaging 
results, the patient was diagnosed with HH with 
secondary pulmonary haemosiderosis. He was 
started on a weekly phlebotomy schedule for the 
goal ferritin of 50 ng/mL, while holding phlebotomy 
if haematocrit reached 33%. During follow-up, a 
laboratory test showed a ferritin of 1223 ng/mL and 
haemoglobin of 13.4 g/dl. The patient was placed 
on twice weekly phlebotomy (500 ml) with oral fluid 
replacement and a course of prednisone 40 mg daily 
for 2 weeks, tapered down to 30 mg for 2 weeks 
and then to 20 mg daily, as well as a prophylaxis 
sulfamethoxazole/trimethoprim (800/160 mg tablet) 
every alternate day, 3  days a week. At 3-month 
follow-up, he reported an improvement in his fatigue. 
A repeat chest CT was conducted after 5 months of 
prior CT [Figure 4] and it showed minimal residual 
abnormality with a reported improvement in diffuse 
reticular nodular opacities.
Discussion
The presentation of HH can vary depending 
on the severity of iron overload, the organ 
Figure 4: Ferri Scan shows that the transverse relaxation rate transferrin saturation was >45% and his liver iron content 
per dry liver weight was approximately 29 mg/g (normal is <1.8 mg/g)
Figure 3: Computed tomography (CT) chest performed 
5  months after initial CT scan with minimal residual 
abnormality with a reported improvement in diffuse 
reticular nodular opacities
Case ReportJ Cancer Allied Spec 2020;6(1):4
Journal Of Cancer & Allied Specialties 4
involved and the presence of other conditions 
that may lead to organ dysfunction. Before our 
understanding of the genetics of HH and the 
HFE gene, the majority of patients presented 
with symptoms caused by iron accumulation. 
Analysis of a population of patients from 1959 
to 1992 with haemochromatosis concluded that 
75% of individuals presented with abnormalities 
in liver function tests, 74% of patients had 
weakness and lethargy, 70% of patients presented 
with hyperpigmentation, 48% of patients had 
concurrent diabetes mellitus, 44% of patients 
had arthralgia, 31% of patients presented with 
electrocardiogram abnormalities and 45% of 
male patients had impotence at the time of 
presentation.[12] While there is a wide array 
of possible manifestations of HH, pulmonary 
haemosiderosis is rarely reported.
At present, routine availability of iron studies and 
genetic testing has led to earlier diagnosis and less 
severe progression of the disease. A more recent 
study found that 76% of individuals who were 
diagnosed with HH were asymptomatic at the time 
of testing.[13] Pulmonary haemosiderosis is not a 
common presenting sign of HH and is more often 
a result of recurrent episodes of diffuse alveolar 
haemorrhage. This may be due to infection, 
rheumatic disease, medications or inhalation 
exposures; however, the aetiology of pulmonary 
haemosiderosis is often unknown.[14]
Pulmonary haemosiderosis secondary to 
haemochromatosis has been reported once 
previously in the Spanish medical literature in 
Archivos de Bronconeumologia in 1995.[15] In this 
case report, authors performed a transbronchial 
biopsy, which confirmed iron deposits in alveolar 
macrophages. Pathognomic feature of pulmonary 
haemosiderosis is lung biopsy, which should be 
suggestive for the presence of haemosiderin-laden 
macrophages. However, this was no conducted in 
the present case report due to genetic evidence 
of HH, the imaging findings and the overall 
improvement in symptoms following repeated 
therapeutic phlebotomy.
Here, we report a case of a 49-year-old male with an 
elevated ferritin level who presented with shortness 
of breath and chest pain. His symptoms were likely 
due to haemosiderosis secondary to HH which 
was confirmed with iron studies, genetic testing 
and FerriScan magnetic resonance imaging. With 
this report, we hope to illuminate a rare possible 
manifestation of HH and encourage further research 
to assess if more patients with HH have pulmonary 
findings.
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